Quinn Opportunity Partners LLC Takes $598,000 Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Quinn Opportunity Partners LLC acquired a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 12,500 shares of the biopharmaceutical company's stock, valued at approximately $598,000.

A number of other institutional investors have also added to or reduced their stakes in the business. CBIZ Investment Advisory Services LLC acquired a new stake in Halozyme Therapeutics in the fourth quarter valued at approximately $29,000. Heck Capital Advisors LLC purchased a new position in Halozyme Therapeutics in the 4th quarter worth $29,000. Smartleaf Asset Management LLC increased its holdings in shares of Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock valued at $42,000 after purchasing an additional 197 shares during the period. Venturi Wealth Management LLC acquired a new stake in shares of Halozyme Therapeutics during the fourth quarter worth about $69,000. Finally, Parkside Financial Bank & Trust increased its holdings in Halozyme Therapeutics by 21.8% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock worth $86,000 after buying an additional 322 shares during the period. Hedge funds and other institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Price Performance

Shares of HALO traded down $2.46 during mid-day trading on Wednesday, hitting $58.82. The company's stock had a trading volume of 1,707,110 shares, compared to its average volume of 1,415,639. The firm has a 50-day simple moving average of $60.36 and a 200 day simple moving average of $54.99. Halozyme Therapeutics, Inc. has a 1-year low of $37.73 and a 1-year high of $66.00. The firm has a market capitalization of $7.27 billion, a P/E ratio of 17.15, a P/E/G ratio of 0.42 and a beta of 1.32. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14.

Remove Ads

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping analysts' consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The business had revenue of $298.01 million for the quarter, compared to analysts' expectations of $285.74 million. Analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $58.69, for a total value of $293,450.00. Following the completion of the transaction, the director now owns 33,611 shares in the company, valued at $1,972,629.59. This represents a 12.95 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael J. Labarre sold 10,000 shares of the business's stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total value of $580,500.00. Following the completion of the transaction, the senior vice president now owns 185,453 shares in the company, valued at approximately $10,765,546.65. This trade represents a 5.12 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 22,200 shares of company stock valued at $1,286,568 in the last ninety days. Insiders own 2.40% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on HALO. Benchmark restated a "buy" rating and set a $75.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Piper Sandler boosted their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research note on Friday, January 10th. HC Wainwright reiterated a "buy" rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Finally, Wells Fargo & Company dropped their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research report on Monday, January 13th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $62.78.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.